Intellia Therapeutics Announces First Quarter 2018 Financial Results
Intellia Therapeutics Announces In Vivo and Ex Vivo Data Presentations at the American Society of Gene and Cell Therapy 21st Annual Meeting
Response to “Unexpected mutations after CRISPR–Cas9 editing in vivo"
Intellia Therapeutics Announces Fourth Quarter and Full Year 2017 Financial Results
Intellia Therapeutics to Present at March Healthcare Investor Conferences
Intellia Therapeutics Announces Publication in Cell Reports of Preclinical Data Demonstrating Effective CRISPR/Cas9 Genome Editing Using Lipid Nanoparticle (LNP) Delivery Technology
Intellia Therapeutics to Present at February Healthcare Investor Conferences
Intellia Therapeutics Names John Leonard, M.D., President and Chief Executive Officer
Intellia Therapeutics Announces New, Robust Genome Editing Data for Sickle Cell Disease at the American Society of Hematology Meeting
Intellia Therapeutics to Present at November Healthcare Investor Conferences